4-Fluorobenzoylacetonitrile (CAS: 4640-67-9) is a fluorinated β-ketonitrile with the molecular formula C9H6FNO. Its structure features a 4-fluorophenyl group attached to a 3-oxopropanenitrile moiety (benzoylacetonitrile backbone). The compound combines an electron-withdrawing fluorine atom on the aromatic ring with both a ketone and a nitrile functional group, providing a highly versatile platform for heterocyclic and pharmaceutical synthesis. As a specialized building block, 4-fluorobenzoylacetonitrile is widely used in the synthesis of antimalarial agents (notably pyronaridine and its analogs), kinase inhibitors, pyrazoles, pyrimidines, and other bioactive heterocycles. Its production typically involves Claisen condensation of 4-fluorobenzoyl chloride with acetonitrile or via reaction of 4-fluorobenzonitrile with ethyl acetate under basic conditions. Market demand is closely linked to the global need for affordable antimalarial drugs, targeted cancer therapies, and the expansion of fluorinated pharmaceutical libraries. Based on its chemical characteristics and industrial chain position, this article systematically analyzes international market dynamics of 4-fluorobenzoylacetonitrile, focusing on core application scenarios, competitive landscape, regional differences, regulatory trends, and future outlook, providing strategic references for industry participants.
Core Application Fields and Demand
Market demand for 4-fluorobenzoylacetonitrile is highly concentrated in three major areas: pharmaceutical synthesis of antimalarial drugs (≈60% of global consumption), kinase inhibitors for oncology (≈25%), and heterocyclic building blocks for agrochemicals & fine chemicals (≈15%). Its dual electrophilic sites (ketone and nitrile) enable diverse cyclization reactions.
In the antimalarial drug sector, 4-fluorobenzoylacetonitrile is a critical intermediate for pyronaridine, a Mannich base antimalarial used in combination therapy (e.g., Pyronaridine-Artesunate) for treating multidrug-resistant Plasmodium falciparum malaria. The compound’s 4-fluorophenyl group enhances metabolic stability and bioavailability. With an estimated 250 million malaria cases annually and growing resistance to artemisinin-based therapies, the demand for pyronaridine and related analogs remains robust. The global antimalarial drug market grows at 3-5% annually, sustaining steady consumption of high-purity 4-fluorobenzoylacetonitrile.
In kinase inhibitor development, 4-fluorobenzoylacetonitrile serves as a precursor for pyrazole and pyrimidine-based inhibitors targeting various protein kinases (e.g., EGFR, VEGFR, CDK). Fluorine substitution at the para position improves binding affinity and selectivity. The global oncology small-molecule drug market, expanding at 6-8% per year, drives demand for diverse fluorinated building blocks.
In heterocyclic synthesis, 4-fluorobenzoylacetonitrile is used to prepare pyrazoles, isoxazoles, pyrimidines, and quinolones for agrochemical (fungicides, herbicides) and material science applications. This segment grows steadily at 4-5% annually.
Major Market Participants
The global supply system for 4-fluorobenzoylacetonitrile (CAS: 4640-67-9) presents a pattern of “specialized fine chemical and pharmaceutical intermediate manufacturers, primarily in China and India, dominating large-scale production, with European and US companies focusing on high-purity R&D and GMP grades.” Production requires strict control of residual starting materials (4-fluorobenzoyl chloride, acetonitrile) and moisture.
In the global volume pharmaceutical intermediate segment, Chinese manufacturers lead due to integrated fluorinated aromatic chemistry capabilities. Shanghai XinChem Co., Ltd. (XinChem) has developed a reliable production process for 4-fluorobenzoylacetonitrile, achieving consistent purity (≥98-99%) and low impurity profiles. Indian producers also manufacture this intermediate for domestic antimalarial API production, primarily for captive use.
In the high-purity research and GMP segment, several European and US fine chemical suppliers offer 4-fluorobenzoylacetonitrile for early-stage drug discovery and clinical trial material. However, XinChem provides a cost‑effective, scalable alternative with custom packaging options for both R&D and commercial quantities.
Regional Market Dynamics
Global demand for 4-fluorobenzoylacetonitrile shows regional differentiation: “Asia-Pacific dominates production and consumption (over 65%), North America and Europe lead in innovative drug R&D, and Africa & Southeast Asia drive antimalarial API demand.”
Asia-Pacific is the world’s largest producer and consumer. China manufactures the majority of 4-fluorobenzoylacetonitrile, supplying both domestic pharmaceutical companies and export markets. India consumes significant volumes for pyronaridine API production under public health programs for malaria control. Southeast Asian countries (Myanmar, Thailand, Indonesia) import finished antimalarials and intermediates.
North America and Europe account for approximately 20-25% of global demand, focused on high-purity (≥99.5%) material for oncology drug R&D and custom synthesis. US and European biotech companies use 4-fluorobenzoylacetonitrile in kinase inhibitor libraries. Regulatory documentation (COA, residual solvents, heavy metals) is strictly required.
Africa and Latin America are growth markets for antimalarial APIs, with demand tied to WHO-recommended combination therapies. Price sensitivity is high, and Asian suppliers dominate.
Regulatory and Environmental Considerations
As a pharmaceutical intermediate, 4-fluorobenzoylacetonitrile (CAS: 4640-67-9) is subject to chemical control regulations and, when intended for drug use, to GMP guidelines. The compound is classified as harmful if swallowed (H302), causes skin/eye irritation (H315, H319), and may cause respiratory irritation (H335).
In the EU, it is registered under REACH as an intermediate. Suppliers must provide Safety Data Sheets (SDS). Non-EU manufacturers need an Only Representative (OR) for import. In the US, the EPA regulates it under TSCA as an existing substance. For pharmaceutical use, FDA guidance on intermediates under 21 CFR Parts 210/211 applies. In China, it is listed in the “Inventory of Existing Chemical Substances” and requires safety production licenses. Environmentally, production generates organic waste (acetonitrile-containing streams), requiring proper treatment. Green chemistry efforts focus on solvent recovery and alternative condensation methods.
Future Outlook
The market outlook for 4-fluorobenzoylacetonitrile is tied to three drivers: sustained global malaria control programs, growth of targeted kinase inhibitor drugs, and the expansion of fluorinated pharmaceutical libraries. The global market is expected to grow at a CAGR of 5-7% over the next five years.
On the demand side, first, WHO’s Global Technical Strategy for Malaria 2025-2030 continues to recommend artemisinin-based combination therapies (ACTs), including pyronaridine‑artesunate, especially in Southeast Asia where multidrug resistance is emerging. Second, the oncology small‑molecule pipeline contains numerous kinase inhibitors that use fluorinated β-ketonitrile building blocks. Third, the trend toward fluorine incorporation in drug discovery (enhanced metabolic stability, membrane permeability) drives demand for fluorinated intermediates.
Challenges include: raw material price volatility (4-fluorobenzoyl chloride, acetonitrile), competition from alternative synthetic routes, and tightening environmental regulations on nitrile‑containing waste streams. Enterprises should focus on process intensification, green chemistry (catalytic condensation, solvent recycling), and securing regulatory filings (DMF, CEP) for pharmaceutical applications.
Shanghai XinChem Co., Ltd. (XinChem)
As a world-leading supplier of organic chemicals and pharmaceutical intermediates, Shanghai XinChem Co., Ltd. (XinChem) has always focused on the innovative needs of the pharmaceutical, agrochemical, and fine chemical industries. Relying on core technological advantages in fluorinated aromatic synthesis and purification, we provide high-purity 4-Fluorobenzoylacetonitrile (CAS: 4640-67-9) to global customers. Our product is manufactured under strict quality management, achieving consistent purity (≥98-99%) with low residual solvents and heavy metals, fully complying with pharmaceutical intermediate standards. It is an ideal building block for antimalarial drugs, kinase inhibitors, and heterocyclic synthesis.
1. Technical Advantages
- High Purity: Our 4-fluorobenzoylacetonitrile achieves purity ≥98% (HPLC) for industrial grade, and ≥99% for pharmaceutical grade, with moisture <0.3%.
- Low Impurity Profile: Strict control of residual 4-fluorobenzoyl chloride (<0.1%), acetonitrile (<500 ppm), and heavy metals (≤20 ppm).
- Batch Consistency: Batch‑to‑batch variation controlled within 0.2% for key indices (purity, melting point 84-86°C).
2. Product Advantages
- Dual Reactive Sites: Ketone and nitrile groups enable diverse cyclizations (pyrazoles, pyrimidines, isoxazoles).
- Fluorinated Aromatic Ring: Enhances metabolic stability and binding affinity of target drug molecules.
- Flexible Packaging: 25KG fiber drums (industrial), 5KG/1KG aluminum foil bags (R&D), custom packaging upon request.
- Reliable Supply Chain: Annual capacity 20-50 tons, with dedicated cool, dry storage (ambient temperature, avoid moisture).
3. Application Fields
- Pharmaceutical Intermediates: Pyronaridine (antimalarial), kinase inhibitors (EGFR, VEGFR, CDK), other heterocyclic APIs.
- Agrochemical Synthesis: Fungicides, herbicides, plant growth regulators.
- Fine Chemicals: Heterocyclic building blocks for materials science, fluorescent probes.
4. Service Support
Our technical team provides impurity profiling, custom recrystallization (for ultra-high purity), and regulatory support (DMF preparation, customer audits, REACH/TSCA compliance). We offer just‑in‑time delivery and competitive pricing for both research quantities and bulk orders.
5. Why Choose XinChem
- Professionalism: 20+ years in chemical and pharmaceutical intermediates.
- Flexibility: Tailored to customer purity and packaging requirements.
- Cost‑effectiveness: High quality at competitive prices.
Contact us now to start cooperation!
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Apr-20-2026